Report of Foreign Issuer (6-k)
May 16 2019 - 7:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
W
ashington,
D.C.
20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of May 2019
Commission
File Number: 001-37643
KITOV
PHARMA
LTD.
(Translation
of registrant’s name into English)
One
Azrieli Center, Round Tower,
Tel
Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Kitov
Pharma Ltd. (the “Company” or the “Registrant”) is announcing that it has made available a presentation
that its CEO, Isaac
Israel, is presenting at the 18th MIXiii-BIOMED Conference and Exhibition, on May 16, 2019 in Tel Aviv, Israel. The presentation
gives an overview of Kitov’s clinical development plans for its oncology candidate NT-219, including disclosing its first
indication for a phase 1/2 clinical trial and trial design. The presentation is attached hereto as Exhibit 99.1
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
KITOV
PHARMA LTD.
|
|
|
May
16, 2019
|
By:
|
/s/
Isaac Israel
|
|
|
Isaac
Israel
|
|
|
CEO
and Director
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024